European Physician Adoption of Advanced Mobile Activities is Increasing

Manhattan ResearchAs mobile devices become more advanced, European physicians are turning to them for a number of uses in their professional practice, according to a recent study by Manhattan Research. About half of online European physicians check email on their mobile devices while nearly four in ten search on a mobile web browser. When it comes to mobile activities for medical content, physicians are currently more likely to conduct straightforward advanced tasks such as reading medical news or checking treatment guidelines, but as physicians' mobile proficiency continues to increase and as browsing capabilities improve, physicians will begin to perform more complex, interactive activities on these devices, such as social networking and patient monitoring.

"As in the U.S., mobile devices are streamlining the medical profession in Europe by allowing doctors to communicate and access clinical resources throughout the day," said Joe Farris, President of Manhattan Research. "While the largest current opportunity for connecting with European physicians is through brief, text-based content, there's future market potential for richer, more engaging mobile interactions."

Complimentary White Paper
Manhattan Research's European eHealth Landscape is a complimentary white paper discussing some of the latest trends in how physicians and patients across Europe use the Internet and technology for health purposes. To access the report, please visit http://www.manhattanresearch.com/research/white-papers/european-ehealth-landscape.aspx.

Manhattan Research eHealth Trends Podcast Series
Manhattan Research produces monthly podcasts on a variety of consumer and physician eHealth topics. In the latest episode, "EU vs. US physicians," Healthcare Analyst Miranda Manganaro discusses differences between European and US physicians when it comes to technology adoption and behavior. Free subscriptions are available immediately via iTunes at http://tinyurl.com/mRiTunes and you can listen to the entire series at http://www.manhattanresearch.com/podcast.

About Taking the Pulse® Europe
Taking the Pulse® Europe is Manhattan Research's market research and advisory service focused on how physicians across Western Europe use the Internet and technology for clinical purposes and for engaging with pharmaceutical companies. Taking the Pulse® Europe v9.0 was fielded online in Q4 2009 among 1,125 practicing physicians in Germany, Spain, France, Italy, and the United Kingdom.

Taking the Pulse® Europe provides in-depth market research on many other physician technology and digital marketing topics, including email communication, smartphone ownership/mobile activities, online journals, virtual conferences, social networking, online video, health and medical website visitation, search engines, patient education, pharma website visitation, videoconferencing with reps, and electronic detailing. In addition to a comprehensive view of the European physician market, clients can also gain insight into the online resource and communication trends for specific country and specialist segments. For more information, please visit http://www.manhattanresearch.com/ttpeu.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the U.S., Europe, and Asia.

For information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...